Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Genocea Biosciences stock
Learn how to easily invest in Genocea Biosciences stock.
Genocea Biosciences Inc is a biotechnology business based in the US. Genocea Biosciences shares (GNCA) are listed on the NASDAQ and all prices are listed in US Dollars. Genocea Biosciences employs 74 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Genocea Biosciences
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – GNCA – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Genocea Biosciences stock price (NASDAQ: GNCA)Use our graph to track the performance of GNCA stocks over time.
Genocea Biosciences shares at a glance
|Latest market close||$0.02|
|52-week range||$0.01 - $2.27|
|50-day moving average||$0.13|
|200-day moving average||$0.98|
|Wall St. target price||$3.08|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.53|
Buy Genocea Biosciences shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Genocea Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Genocea Biosciences price performance over time
|1 week (2022-06-28)||-8.54%|
|1 month (2022-06-01)||-75.00%|
|3 months (2022-04-05)||-98.88%|
|6 months (2022-01-05)||-98.57%|
|1 year (2021-07-02)||-99.33%|
|2 years (2020-07-02)||-99.32%|
|3 years (2019-07-05)||3.83|
|5 years (2017-07-05)||5.27|
Genocea Biosciences financials
|Revenue TTM||$1.9 million|
|Gross profit TTM||$1.6 million|
|Return on assets TTM||-57.59%|
|Return on equity TTM||-525.78%|
TTM: trailing 12 months
Genocea Biosciences share dividends
We're not expecting Genocea Biosciences to pay a dividend over the next 12 months.
Have Genocea Biosciences's shares ever split?
Genocea Biosciences's shares were split on a 1:8 basis on 21 May 2019. So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Genocea Biosciences shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Genocea Biosciences shares which in turn could have impacted Genocea Biosciences's share price.
Genocea Biosciences share price volatility
Over the last 12 months, Genocea Biosciences's shares have ranged in value from as little as $0.012 up to $2.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genocea Biosciences's is 1.9474. This would suggest that Genocea Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Genocea Biosciences overview
Genocea Biosciences, Inc. , a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. .
Frequently asked questionsWhat percentage of Genocea Biosciences is owned by insiders or institutions?
Currently 6.222% of Genocea Biosciences shares are held by insiders and 40.931% by institutions. How many people work for Genocea Biosciences?
Latest data suggests 74 work at Genocea Biosciences. When does the fiscal year end for Genocea Biosciences?
Genocea Biosciences's fiscal year ends in December. Where is Genocea Biosciences based?
Genocea Biosciences's address is: 100 Acorn Park Drive, Cambridge, MA, United States, 02140 What is Genocea Biosciences's ISIN number?
Genocea Biosciences's international securities identification number is: US3724274010 What is Genocea Biosciences's CUSIP number?
Genocea Biosciences's Committee on Uniform Securities Identification Procedures number is: 372427104
More guides on Finder
How to buy Citrine Global (CTGL) stock when it goes public
Everything we know about the Citrine Global IPO, plus information on how to buy in.
How to buy Genelux Corporation (GNLX) stock when it goes public
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
How to buy Magic Empire Global (MEGL) stock when it goes public
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
How to buy Intchains Group (ICG) stock when it goes public
Everything we know about the Intchains Group IPO, plus information on how to buy in.
How to buy Biostage (BSTG) stock when it goes public
Everything we know about the Biostage IPO, plus information on how to buy in.
How to buy Wang & Lee Group (WLGS) stock when it goes public
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
How to buy OptMed (OMED) stock when it goes public
Everything we know about the OptMed IPO, plus information on how to buy in.
How to buy Lichen China (LICN) stock when it goes public
Everything we know about the Lichen China IPO, plus information on how to buy in.
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Ask an Expert